Sai Life Sciences is a pure-play, full-service CDMO driven by a vision to support the launch of 25 new medicines by 2025. It works with global innovator pharma and biotech companies, accelerating the discovery, development and manufacture of complex small molecules. Over the past two decades, Sai Life Sciences has served a diverse set of NCE development programs, consistently delivering value based on its quality and responsiveness. Today, it works with 7 of the top 10 large pharma companies, as well as several small and mid-sized pharma & biotech companies. As one of India’s fastest growing CDMOs, the company is investing over US $ 150 Mn in augmenting its R&D and manufacturing capabilities. Sai Life Sciences is backed by TPG Capital and HBM Healthcare Investments.